Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes

10 Feb 2023

Abstract excerpt

To examine the prognostic value of claudin 18.2 (CLDN18.2) and human epidermal growth factor receptor-2 (HER-2) expression in patients with resected pancreatic ductal adenocarcinoma (PDAC). This study enrolled patients who underwent surgery and were diagnosed with PDAC at Suleyman Demirel University Hospital, Turkey between 2015 and 2019. Sixty-eight patients with resected PDAC treated at a medical oncology...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AI in cancer detection
Share to Barrier Structure and Function Studies
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36820561
DOI: 10.1097/md.0000000000032882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomesPMID 36820561Read ↗

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

Prognostic significance of Claudin18.2 expression in patients with gastric cancer: Insights from original research and meta-analysisSemantic proximity Read ↗

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapySemantic proximity Read ↗

TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Identification of CLDN18 as a potential diagnostic biomarker and therapeutic target for pancreatic cancer based on multiomic analysisSemantic proximity Read ↗

Claudin-1, A Double-Edged Sword in CancerSemantic proximity Read ↗

CKS2 Predicts A Poor Prognosis and Contributes to Malignant Progression of Pancreatic CancerSemantic proximity Read ↗

Immunohistochemical expression of Claudin18.2 in borderline and malignant gynecologic tumors: Results from a pilot studySemantic proximity Read ↗

Identification of Key Claudin Genes Associated With Survival Prognosis and Diagnosis in the Colon Cancer Through Integrated Bioinformatic Analysis‏.Semantic proximity Read ↗

Identification of key claudin genes associated with survival prognosis and diagnosis in colon cancer through integrated bioinformatic analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.